Veeva shares climb 8.2%, market value up $3.3 billion after AI-driven sales boost forecast

Veeva shares climb 8.2%, market value up $3.3 billion after AI-driven sales boost forecast

PLEASANTON, California, August 26, 2026, 17:41 EDT — Veeva Systems (VEEV.N) advanced 8.2%, adding $3.3 billion in market capitalization, after the company raised its sales outlook on the back of increasing demand for its artificial intelligence products.

  • Veeva shares rose 8.24% after hours to $265.09, compared with their closing price of $244.91.
  • Revenue for the fiscal second quarter increased 18% to $928.0 million.
  • Revenue from R&D and Quality subscriptions rose 19% to reach $419.4 million.
  • Veeva increased its full-year revenue midpoint by $44.5 million.

Veeva Systems Inc. (NYSE:VEEV) shares surged as the life-sciences software firm surpassed quarterly forecasts and lifted its full-year guidance. The stock climbed to $265.09 at 17:40 EDT, up 8.24% in after-hours trading latest quote.

Stock chart for NYSE:VEEV

The action represented an approximate $3.28 billion increase in equity value. This is double Veeva’s projected yearly operating cash flow and nearly 74 times higher than the rise in revenue guidance.

Revenue for the fiscal second quarter rose 18% to $928.0 million, surpassing the analyst forecast of $905.4 million by 2.5%. Adjusted earnings came in at $2.35 per share, exceeding the consensus estimate of $2.22 estimate comparison.

MetricQ2 FY2027Q2 FY2026Change
Total revenue$928.0 million$789.1 million+18%
Subscription revenue$766.8 million$659.2 million+16%
GAAP operating income$275.0 million$195.9 million+40%
Adjusted operating income$415.9 million$352.6 million+18%
Normalized billings$768 million$666 million+15%

Subscriptions related to R&D and Quality accounted for the largest share, with revenue climbing 19% to $419.4 million. Revenue from commercial subscriptions grew 13%, reaching $347.4 million earnings presentation.

Chief Executive Peter Gassner reported that Vault CRM achieved its strongest quarter to date. Over 180 customers are currently using the system. Twelve out of the top 20 biopharma firms have made global commitments company release.

Veeva disclosed that five initial customers have adopted its Falcon agent platform. Veeva Safety surpassed 100 customers. More than 30 customers were added to Veeva’s Quality products in the quarter.

The company now expects full-year revenue between $3.682 billion and $3.687 billion, up from the earlier forecast of $3.635 billion to $3.645 billion. Adjusted operating income guidance climbed by $30 million to roughly $1.64 billion previous outlook.

Veeva raised its adjusted earnings outlook to $9.21 per share, up from $9.05. The company forecasts adjusted operating cash flow of about $1.6 billion, suggesting a margin close to 43%.

The forecast for the third quarter indicates a slight slowdown. Projected revenue of $932 million to $935 million suggests growth of roughly 15%. Subscription revenue is anticipated to be close to $782 million.

GAAP operating income increased by 40%, doubling the pace of revenue expansion. Adjusted operating margin remained steady at 44.8%. GAAP operating cash flow for the quarter was little changed at $238.7 million.

Veeva allocated $472.7 million to buybacks in the first half. Its after-hours value increase was almost seven times larger than that amount. The company reported $7.24 billion in cash and short-term investments.

Of 30 ratings, Wall Street gives an average recommendation of Overweight. After-hours, the price at $265.09 was 5.6% higher than the $251.04 average target, but 0.3% under the $266 median analyst estimates.

The shares changed hands at 28.8 times Veeva’s updated adjusted earnings outlook. That valuation expects sustained subscription expansion. It offers little cushion if customer migrations slow down.

Risks persist. Third-quarter growth is forecast to be slower than in the previous quarter. Vault CRM has secured 12 commitments from the top 20, with decisions still pending from eight customers. Delays in deployments may occur due to competition, product-security issues, or reduced funding in the drug industry.

Investors are set to gauge the rally as third-quarter revenue falls within the $932 million to $935 million range. Maintaining R&D and Quality expansion close to 19% would help underpin the increased annual outlook.

Veeva Stock Jumps 8.2%, Adding $3.3 Billion as AI Sales Lift Outlook
NYSE: VEEV · Company stock move

AI and life-sciences cloud growth lift Veeva

Fiscal Q2 2027 earnings · closed market / after-hours reaction
Price snapshot: August 26, 2026, 17:40:48 EDT
Results and guidance: August 26, 2026
After-hours price
$265.09
vs. $244.91 regular close
After-hours move
+8.24%
+$20.18 per share
Implied value added
≈$3.28B
162.44M shares × $20.18
Q2 revenue
$928.0M
+18% year over year

Quarterly operating scorecard

RevenueSubscriptionGAAP op. incomeAdj. op. incomeNorm. billings $789M$928M$659M$767M$196M$275M$353M$416M$666M$768M
Q2 FY2026Q2 FY2027

Investor bridge

Value gain / FY OCF
2.0×
Value gain / guidance raise
73.7×
Price / guided EPS
28.8×
Adj. op. margin
44.8%

The after-hours value gain is about twice Veeva’s $1.6 billion annual adjusted operating-cash-flow guide.

FY2027 guidance reset

MetricPriorNewChange
Revenue midpoint$3.640B$3.6845B+$44.5M
Adjusted operating income≈$1.610B≈$1.640B+$30M
Adjusted EPS≈$9.05≈$9.21+$0.16
Adjusted operating cash flow≈$1.600B43% margin

Revenue mix and product signals

SignalLatestGrowth / status
R&D and Quality subscription$419.4M+19%
Commercial subscription$347.4M+13%
Vault CRM customers live>1805 top-20 live
Top-20 CRM commitments12 of 202 added in August
Falcon early adopters5Initial go-lives due in 2026

Street positioning

30 ratingsOverweight consensus16 Buy5 Overweight8 Hold1 Sell
Average target$251.04 · 5.6% below
Median target$266 · 0.3% upside
Target range$165–$340
Pre-report FY2027 EPS estimate$9.06
New company EPS guide$9.21

Analyst snapshot dated August 26, 2026; comparisons use the 17:40:48 EDT after-hours price.

Risk monitor

  • Growth cadence: Q3 revenue guidance implies roughly 15%, below Q2’s 18%.
  • Valuation: the stock traded above the pre-report average target.
  • CRM conversion: eight top-20 biopharma decisions remain outside the disclosed commitments.
  • Operating exposure: competition, security failures or weaker drug funding could delay deployments.
  • Cash timing: quarterly GAAP operating cash flow was nearly flat year over year.
Sources: Veeva fiscal Q2 2027 earnings release and presentation; Veeva fiscal Q1 2027 outlook; MarketWatch quote and analyst estimates; Yahoo Finance after-hours data. Market-value calculations use 162.44 million shares outstanding and may differ from fully diluted measures.
Leokadia Głogulska

Leokadia Głogulska is a financial and technology journalist at TS2.tech. Her coverage ranges from stocks and artificial intelligence to space technology and developments across global markets. She graduated from Wrocław University of Economics and Business and worked in financial analysis before becoming a business journalist.

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Kodiak Gas Services

NYSE:KGS • Energy infrastructure 88/100 • ★★★★☆
#2 STRONG BUY

Neurocrine Biosciences

NASDAQ:NBIX • Healthcare 87/100 • ★★★★☆
#3 STRONG BUY

Alphabet Class A

NASDAQ:GOOGL • Communication services 85/100 • ★★★★☆
#4 BUY ON WEAKNESS

Applied Materials

NASDAQ:AMAT • Semiconductor equipment 84/100 • ★★★★☆
#5 ACCUMULATE

JPMorgan Chase

NYSE:JPM • Financials 80/100 • ★★★★☆
View full portfolio
Editorial model selection. Not personalised advice.
Synopsys Shares Drop 2.8%, Wiping Out $2.2 Billion After Upgraded AI-Driven Outlook
Previous Story

Synopsys Shares Drop 2.8%, Wiping Out $2.2 Billion After Upgraded AI-Driven Outlook